A single centre, open label, first in human, phase 1 dose escalating study to evaluate the safety, tolerability and preliminary efficacy of an autologous cancer vaccine, RGSH4K, administered intradermally in patients with advanced cancers.

Trial Profile

A single centre, open label, first in human, phase 1 dose escalating study to evaluate the safety, tolerability and preliminary efficacy of an autologous cancer vaccine, RGSH4K, administered intradermally in patients with advanced cancers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2016

At a glance

  • Drugs RGSH4K (Primary) ; Freund's adjuvant; Streptavidin
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms ACTIVATE
  • Sponsors Regeneus ltd
  • Most Recent Events

    • 19 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top